NCT06342908 — Jonsson Comprehensive Cancer Center neoantigen vaccine trial
A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma
Registry record
| Registry ID | NCT06342908 ↗ |
|---|---|
| Lead sponsor | Jonsson Comprehensive Cancer Center |
| Collaborators | — |
| Phase | Phase 1 |
| Status | Active Not Recruiting |
| Indication | Diffuse Hemispheric Glioma, H3 G34-Mutant |
| Enrollment | 6 participants (target) |
| Start date | 2024-06-14 |
| Primary completion | 2027-03-08 (est.) |
| Last registry update | 17 Feb 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06342908), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT06342908?
NCT06342908 (A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma) is registered on ClinicalTrials.gov as Phase 1, sponsored by Jonsson Comprehensive Cancer Center.
Is NCT06342908 recruiting?
As of the 2026-02-17 registry update, NCT06342908 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06342908?
The lead sponsor is Jonsson Comprehensive Cancer Center.
What condition does NCT06342908 study?
The registered condition is Diffuse Hemispheric Glioma, H3 G34-Mutant. Primary completion is listed as 2027-03-08 (estimated).
Are results available for NCT06342908?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06342908.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.